Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma × surufatinib × Clear all

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 5 Cholangiocarcinoma 3 Thyroid Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Neuroendocrine Tumors 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Biliary Tract Neoplasms 2 Sarcoma 1 Refractory Metastatic Digestive System Carcinoma 1 Osteosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Locally Advanced Pancreatic Cancer 1 Head and Neck Cancers - Salivary Gland 1 Gallbladder Neoplasms 1 Differentiated Thyroid Cancer 1 Colorectal Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoma 1 Breast Neoplasms 1 Appendiceal Neoplasms 1 Advanced Non-Small Cell Lung Cancer 1 Advanced Colorectal Cancer 1 Adenoma, Islet Cell 1

Interventions

Doxorubicin 52 Ifosfamide 32 Gemcitabine 25 Radiotherapy 21 Filgrastim 21 Cyclophosphamide 21 Docetaxel 17 Vincristine 15 Etoposide 15 Trabectedin 14 Nivolumab 14 pembrolizumab 12 pazopanib 12 apatinib 12 Cisplatin 12 Magnetic Resonance Spectroscopy 11 Sirolimus 10 Irinotecan 10 Carboplatin 10 Temozolomide 9 Surgical Procedures, Operative 9 Sorafenib 9 anlotinib 8 Ipilimumab 8 Dactinomycin 8 Bevacizumab 8 Topotecan 7 Paclitaxel 7 palbociclib 6 camrelizumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05106777 2023-04-12

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Sun Yat-sen University

Phase 2 Unknown

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡